University of Miami Sylvester Comprehensive Cancer Center - Miami
Welcome,         Profile    Billing    Logout  
 21 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wolfson, Aaron H
GOG-3039, NCT04393285: Abemaciclib and Letrozole to Treat Endometrial Cancer

Active, not recruiting
2
53
US
Abemaciclib, Letrozole
Gynecologic Oncology Group, Eli Lilly and Company
Endometrial Cancer
12/24
12/25
NCT05603910: Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Recruiting
1
18
US
Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Hypofractionated External Beam Radiation Therapy
Aaron Wolfson
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
04/25
04/30
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
457
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
Feun, Lynn G
NCT02339571: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Recruiting
2/3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Elastography, MRE, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
06/33
06/33
NCT05199285: A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Recruiting
2
40
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Academic and Community Cancer Research United, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
01/24
01/27
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NCT06627244: Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Recruiting
2
30
US
Tebentafusp, Tebentafusp-tebn, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization, Y-90 TARE
University of Miami, Immunocore Ltd
Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
02/28
02/31
NCT04462406: Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Recruiting
2
150
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
08/26
08/26
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Active, not recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/25
12/25
Lima, Caio Max S Rocha
COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting
3
120
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
06/27
06/27
NCT01835041: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed
1
21
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
02/17
03/23
NCT02232152: CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed
1
19
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
02/19
01/23
Civantos, Francisco
ASP-1929-301, NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruiting
3
135
Japan, US, RoW
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Rakuten Medical, Inc.
Head and Neck Cancer
12/25
12/25
NRG-HN006, NCT04333537: Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Recruiting
2/3
618
Canada, US
Computed Tomography (CT), CAT, CAT scan, Computed Tomography, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Imaging Agent, Image Enhancement Agent, Neck Dissection, Planar Imaging, Sentinel Lymph Node Biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
NRG Oncology, National Cancer Institute (NCI)
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
05/31
05/36
Pereira, Denise
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Ramos, Juan Carlos
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT02737046: Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Active, not recruiting
2
15
US
Belinostat, PXD101, Beleodaq®, Zidovudine, AZT, Interferon-Alfa-2b, IFN-α-2b, Pegylated Interferon-Alfa-2b, PEG-IFN-α-2b
University of Miami
Adult T-cell Leukemia-Lymphoma, ATLL
07/24
07/25
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Active, not recruiting
2
23
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
12/25
06/26
NCT04305691: Trial of Ixazomib for Kaposi Sarcoma

Recruiting
2
41
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma, Skin
05/25
05/26
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Active, not recruiting
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
Imagine-1, NCT04713475 / 2020-001109-22: Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Active, not recruiting
1/2
26
Europe, Canada, US, RoW
PBGM01
Passage Bio, Inc.
GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
02/26
02/29
AMC-105, NCT04139304: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Active, not recruiting
1
15
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LEUROCRISTINE, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
AIDS Malignancy Consortium, National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, AIDS and Cancer Specimen Resource, The Emmes Company, LLC
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
08/27
NCT05321940: Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

Withdrawn
1
18
NA
STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, STING (Stimulator of Interferon Genes)-Dependent Activators, STAVs-Loaded Autologous Leukemic Cells, STING-dependent innate immune agonists, Dendritic Cell Vaccine, DC Vaccine
Juan C. Ramos, MD
Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Adult T-Cell Leukemia/Lymphoma
11/25
11/26
OR-ARI-EAP-NPC, NCT04316637: Early Access Program With Arimoclomol in US Patients With NPC

Available
N/A
US
Arimoclomol
ZevraDenmark
Niemann-Pick Disease, Type C
 
 
E²-RADIatE, NCT03818503: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Recruiting
N/A
2000
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Cancer
04/26
04/26
PETIFI, NCT05688592: Usefulness of PET-CT for Invasive Fungal Infection

Recruiting
N/A
224
Europe
PET-CT, Before-and-after study
Puerta de Hierro University Hospital, Gilead Sciences
Invasive Fungal Infections
10/24
12/24
VRAM, NCT03221244: Virtual Reality Attention Management

Recruiting
N/A
50
US
VR Treatment, VR Active Control
University of California, Davis, National Institute of Mental Health (NIMH)
ADHD
09/26
07/27
Avisar, Eli
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
NCT05929001: Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection

Active, not recruiting
N/A
101
US
University of Miami
Lymphedema
12/24
01/26
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Escalon, Maricer
MPAR-101, NCT05090280: Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-)

Completed
1
111
US
PF614 solution, PRF06104, Oxycodone prodrug, Naltrexone Hydrochloride, ReVia, Nafamostat Mesylate, Futhan
Ensysce Biosciences, Quotient Sciences, National Institute on Drug Abuse (NIDA)
Pharmacokinetics
04/23
04/23
Lossos, Izidore
NCT02507336: Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

Completed
2
2
US
Thalidomide, Thalomid
University of Miami
Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
08/23
08/23
NCT00878254: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Checkmark P2 data: ASH 2012
Nov 2012 - Nov 2012: P2 data: ASH 2012
Active, not recruiting
2
25
US
G-CSF, Filgrastim, Neupogen, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Cytarabine, AraC, Doxorubicin, Adriamycin, Etoposide, VP16, Ifosfamide, Ifex, Leucovorin, Folinic acid, Mesna, Mesnex, Methotrexate, MTX, Vincristine, Oncovin
University of Miami
Mantle-Cell Lymphoma
06/24
09/27
NCT06569680: Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma

Recruiting
2
35
US
Mosunetuzumab, ML44933, Lunsumio, Mosunetuzumab-axgb
Izidore Lossos, MD, Genentech, Inc.
Extranodal Marginal Zone Lymphoma
12/30
12/30
NCT06796998: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Not yet recruiting
2
25
US
Epcoritamab
Izidore Lossos, MD, Genmab, AbbVie
Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
05/28
11/29
NCT05296070: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

Recruiting
2
50
US
Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg
University of Miami, ADC Therapeutics S.A.
Marginal Zone Lymphoma
06/28
06/29
Center, CIS Contact
No trials found

Download Options